NDA 022306 · Altathera Pharms LLC
Sotalol Hydrochloride
Sotalol Hydrochloride · Intravenous
OrphanLast checked: Nov 20, 2026Latest source record: Jul 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Jul 2, 2009
Approved uses
3
Original approval plus efficacy supplements
Registered trials
57
14 Phase 3, 9 recruiting
FAERS reports
2,515
2,111 serious, 254 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: LIFE THREATENING PROARRHYTHMIA Sotalol can cause life threatening ventricular tachycardia associated with QT interval prolongation. To minimize the risk of drug induced arrhythmia, initiate or up-titrate intravenous sotalol in a facility that can provide continuous electrocardiographic monitoring and cardiac resuscitation [see Dosage and Administration ( 2.3 ) and Warnings and Precautions ( 5.1 )] Do not initiate intravenous sotalol therapy if the baseline QTc is longer than 450 ms. If the QTc prolongs to 500 ms or greater, reduce the dose or discontinue. WARNING: LIFE THREATENING PROARRHYTHMIA See full prescribing information for complete boxed warning. Sotalol can cause life threatening ventricular tachycardia associated with QT interval prolongation. ( 5.1 ) Initiate or reinitiate in a facility that can provide cardiac resuscitation and continuous electrocardiographic...
What it is approved for
From the label in effect Jul 31, 2025.
Sotalol is an antiarrhythmic indicated for: the treatment of life-threatening ventricular tachycardia. ( 1.1 ) the maintenance of normal sinus rhythm in patients with atrial fibrillation or flutter (AFIB/AFL). ( 1.2 ) Limitations of Use Sotalol has not been shown to enhance survival in patients with life-threatening ventricular arrhythmias. ( 1.1 ) Avoid use in patients with minimally symptomatic or easily reversible AFIB/AFL ( 1.2 ) 1.1 Life-Threatening Ventricular Arrhythmia Sotalol is indicated for the treatment of documented, life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia in adult and pediatric patients. Limitations of Use: Sotalol has not been shown to enhance survival in patients with life-threatening ventricular arrhythmias. 1.2 Delay in Recurrence of Atrial Fibrillation/Atrial Flutter Sotalol is indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter (AFIB/AFL)) in adults and pediatric patients with highly symptomatic AFIB/AFL who are currently in sinus rhythm. Limitation of Use: Because sotalol can cause life-threatening ventricular arrhythmias, reserve its use for patients in whom AFIB/AFL is highly symptomatic.
Mechanism: Sotalol has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. Intravenous sotalol is a racemic mixture of d- and l-sotalol. Both isomers have similar Class III antiarrhythmic effects, while the l-isomer is responsible for virtually all of the beta-blocking activity. T he beta-blocking effect of sotalol is non-cardioselective, half maximal at oral doses of about 80 mg/day and maximal at oral doses between 320 and 640 mg/day. Significant beta-blockade occurs at oral doses as...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 23, 2025 Supplement 8 · Efficacy OrphanLetterLabel
- Mar 6, 2020 Supplement 5 · Efficacy OrphanLabelLetter
- Jul 2, 2009 Original approval · Type 3 - New Dosage Form OrphanLabelReviewSummary Review
1 products under this application
- SOTALOL HYDROCHLORIDE · SOTALOL HYDROCHLORIDE 150MG/10ML (15MG/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Sotalol" as an intervention, any sponsor and status, largest first.
- Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation TrialPivotal-lookingCompleted
Mayo ClinicAcademic, hospital or other
NCT00911508 · 2,204 participants · Start Nov 13, 2009 · Primary completion Dec 31, 2017
Drug: Rate or Rhythm Control Therapy · For: Atrial Fibrillation; Arrhythmia
Sites: Little Rock, Arkansas; Los Angeles, California; Sacramento, California · 118 sites in all
- Kansai Plus Atrial Fibrillation TrialPivotal-lookingCompleted
Kyoto University, Graduate School of MedicineAcademic, hospital or other
NCT01477983 · 2,113 participants · Start Nov 2011 · Primary completion Jul 2017
Drug: Antiarrhythmic drug (AAD); Control and 2 more · For: Atrial Fibrillation
Sites: Kyoto, Japan
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT00773201 · 997 participants · Start Feb 2008 · Primary completion Mar 2012
Drug: Sotalol 80 mg · For: Healthy Volunteers
Sites: Paris, France
- Flecainide Safety in Patients With Coronary Artery Disease and Atrial FibrillationPivotal-lookingRecruiting
Universitaire Ziekenhuizen KU LeuvenAcademic, hospital or other
NCT07405671 · 988 participants (planned) · Start Sep 2026 · Primary completion Dec 2029
Drug: flecainide; Sotalol or Amiodarone · For: Atrial Fibrillation (AF); Coronary Artery Disease
Sites: Aalst, Belgium; Bonheiden, Belgium; Bruges, Belgium · 14 sites in all
- Comparing the Effects of Amiodarone, Sotalol, and Placebo in Maintaining Sinus Rhythm in Patients With Atrial Fibrillation Converted to Sinus RhythmPivotal-lookingCompleted
US Department of Veterans AffairsFederal agency
NCT00007605 · 706 participants (planned) · Start Apr 1998 · Primary completion Oct 2002
Drug: Amiodarone; Sotalol · For: Atrial Fibrillation; Cerebrovascular Accident; Death, Sudden
Sites: Tucson, Arizona; No. Little Rock, Arkansas; Fresno, California · 28 sites in all
- Efficacy and Safety Evaluation of Azimilide or Sotalol vs Placebo for Treatment of Patients With Atrial Fibrillation.Pivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT00035451 · 658 participants · Start Feb 2001 · Primary completion Jun 2003
Drug: Azimilide Dihydrochloride; Placebo and 1 more · For: Atrial Fibrillation
Sites: Brussels, Belgium; Yvoir, Belgium; Aix-en-Provence, France · 129 sites in all
- Antiarrhythmic Drugs Assessment in Preventing Atrial FibrillationPivotal-lookingStatus unknown
Xinhua Hospital, Shanghai Jiao Tong University School of MedicineAcademic, hospital or other
NCT02145546 · 600 participants (planned) · Start May 2014 · Primary completion May 2017
Drug: Amiodarone; Propafenone and 1 more · For: Atrial Fibrillation
Sites: Shanghai, China
- Efficacy of Early Rhythm Control Therapy in Patients With Subclinical Atrial FibrillationPivotal-lookingRecruiting
Samsung Medical CenterAcademic, hospital or other
NCT07447297 · 520 participants (planned) · Start Jan 2, 2024 · Primary completion Dec 15, 2027
Drug: early rhythm control group · For: Atrial Fibrillation (AF); Diseases of the Circulatory System; Atrial Flutter
Sites: Seoul, South Korea
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- atrial fibrillation171
- electrocardiogram qt prolonged148
- drug ineffective143
- hypotension123
- dyspnoea117
- bradycardia111
- dizziness110
- drug interaction99
- nausea93
- fatigue92
- fall86
- acute kidney injury72
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 46 |
| 2005 | 31 |
| 2006 | 127 |
| 2007 | 234 |
| 2008 | 30 |
| 2009 | 123 |
| 2010 | 30 |
| 2011 | 79 |
| 2012 | 107 |
| 2013 | 57 |
| 2014 | 66 |
| 2015 | 54 |
| 2016 | 76 |
| 2017 | 95 |
| 2018 | 123 |
| 2019 | 146 |
| 2020 | 110 |
| 2021 | 94 |
| 2022 | 139 |
| 2023 | 149 |
| 2024 | 193 |
| 2025 | 253 |
| 2026 | 153 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treatment for beta-blocker poisoning: a systematic review.
Rotella JA, Greene SL, Koutsogiannis Z, et al. · Clin Toxicol (Phila) 2020 · Systematic Review
- Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia.
Sapp JL, Tang ASL, Parkash R, et al. · N Engl J Med 2025 · Clinical Trial, Phase IV, Comparative Study
- Intravenous Flecainide for Emergency Department Management of Acute Atrial Fibrillation.
Markey GC, Salter N, Ryan J · J Emerg Med 2018 · Meta-Analysis, Systematic Review
- Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia.
Arenal Á, Ávila P, Jiménez-Candil J, et al. · J Am Coll Cardiol 2022 · Multicenter Study, Randomized Controlled Trial
- Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.
Lafuente-Lafuente C, Valembois L, Bergmann JF, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Atrial fibrillation (acute onset).
Lip GY, Apostolakis S · BMJ Clin Evid 2014 · Systematic Review
Sponsor: Altathera Pharms LLC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.